PE20030257A1 - Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 - Google Patents

Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4

Info

Publication number
PE20030257A1
PE20030257A1 PE2002000619A PE2002000619A PE20030257A1 PE 20030257 A1 PE20030257 A1 PE 20030257A1 PE 2002000619 A PE2002000619 A PE 2002000619A PE 2002000619 A PE2002000619 A PE 2002000619A PE 20030257 A1 PE20030257 A1 PE 20030257A1
Authority
PE
Peru
Prior art keywords
sup
sub
aryl
heteroaryl
receptor agonists
Prior art date
Application number
PE2002000619A
Other languages
English (en)
Inventor
Todd Richard Elworthy
Taraneh Mirzadegan
Keith Adrian Murray Walker
David Bernard Smith
Michael Garret Roepel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030257A1 publication Critical patent/PE20030257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A ANALOGOS 8-AZA-11-DESOXI DE PROSTAGLANDINAS DE FORMULA I DONDE A ES (CH2)2, HC=CH; B ES ARILO, HETEROARILO O ESTA AUSENTE; Z ES COOR', CONR'R", CONSO2R', PR'O(OR'), PO(OR')2, TETRAZOL-5-IL; R' Y R" SON H, ALQUILO C1-C6; m ES 1-6; R1 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILALQUILO, HETEROCICLILALQUILO, ARILO, ARILALQUILO, ENTRE OTROS; CUANDO B ES ARILO, HETEROARILO; R3, R4, R5, R6 NO SON A LA VEZ H; R1 ES HETEROCICLILALQUILO, ARILO, HETEROARILO; CUANDO B ESTA AUSENTE, R3, R4, R5, R6 SON TODOS H; R2 ES H, ALQUILO C1-C6, ALQUENILO C1-C6, ALQUINILO C1-C6; R3, R4, R5, R6 SON H, ALQUILO C1-C6; O R3 Y R4, R5 Y R6, R3 Y R5 JUNTO AL ATOMO QUE ESTAN UNIDOS FORMAN ANILLO ALQUILO C3-C7. SON COMPUESTOS PREFERIDOS ACIDO 7-{(R)-2-[(TRANS)-3-(4'-CLORO-2'-METILBIFENIL-3-IL)-3-HIDROXIPROPENIL]-5-OXO-PIRROLIDIN-1-IL}-HEPTANOICO; ACIDO 7-{(R)-2-[3-(4-CLORO-2'-METIL-BIFENIL-3-IL)-3-HIDROXI-PROPIL]-5-OXO-PIRROLIDIN-1-IL}-HEPTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON AGONISTAS DE EP4 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS OSEOS
PE2002000619A 2001-07-16 2002-07-11 Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 PE20030257A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30572701P 2001-07-16 2001-07-16
US37134802P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
PE20030257A1 true PE20030257A1 (es) 2003-03-21

Family

ID=26974750

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000619A PE20030257A1 (es) 2001-07-16 2002-07-11 Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4

Country Status (17)

Country Link
US (1) US6900336B2 (es)
EP (1) EP1409455B1 (es)
JP (1) JP2004521954A (es)
KR (1) KR20040015364A (es)
AT (1) ATE315022T1 (es)
AU (1) AU2002328855B2 (es)
BR (1) BR0211201A (es)
CA (1) CA2451392A1 (es)
DE (1) DE60208568T2 (es)
ES (1) ES2254726T3 (es)
MX (1) MXPA04000456A (es)
PA (1) PA8550201A1 (es)
PE (1) PE20030257A1 (es)
PL (1) PL368046A1 (es)
RU (1) RU2288913C2 (es)
UY (1) UY27384A1 (es)
WO (1) WO2003008377A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455758T1 (de) * 2001-12-20 2010-02-15 Merck Serono Sa Pyrrolidin-derivatie als prostaglandin- modulatoren
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
CA2513652A1 (en) * 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
CA2528179C (en) * 2003-06-06 2013-10-22 Allergan, Inc. Piperidinyl prostaglandin e analogs
WO2005061492A1 (ja) * 2003-12-22 2005-07-07 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれらを有効成分とする薬剤
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
AU2005304764B2 (en) 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
AU2006223514A1 (en) * 2005-03-10 2006-09-21 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2012211448B2 (en) * 2005-03-10 2016-01-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ATE515263T1 (de) * 2005-05-06 2011-07-15 Allergan Inc Substituierte beta-lactame und deren verwendung in der medizin
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
ATE502914T1 (de) * 2006-08-09 2011-04-15 Allergan Inc Therapeutische amide und entsprechende verbindungen
CN101595106B (zh) * 2007-01-31 2014-05-07 阿勒根公司 作为治疗药物的取代的γ内酰胺
JP5566696B2 (ja) * 2007-02-15 2014-08-06 アラーガン インコーポレイテッド 緑内障または上昇眼内圧の治療用ガンマ‐ラクタム類
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
CN101868455B (zh) * 2007-10-23 2013-11-13 阿勒根公司 治疗性的取代的内酰胺
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
MX2010011636A (es) * 2008-04-24 2010-11-25 Allergan Inc Gamma lactamas sustituidas como agentes terapeuticos.
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
US7985765B2 (en) * 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
BRPI0918134B1 (pt) * 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
RU2627842C2 (ru) * 2011-08-02 2017-08-14 Оно Фармасьютикал Ко., Лтд. Средство для улучшения диастолической функции левого желудочка
WO2014015247A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
AU2014229065B2 (en) 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
GB201914585D0 (en) * 2019-10-09 2019-11-20 Heptares Therapeutics Ltd Prostaglandin ep4 receptor antagonist compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2556326A1 (de) 1975-12-13 1977-06-23 Hoechst Ag Neue pyrrolidone und verfahren zu ihrer herstellung
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
EP1121133A1 (en) 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
WO2001046140A1 (en) 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
SK5562003A3 (en) * 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis

Also Published As

Publication number Publication date
WO2003008377A1 (en) 2003-01-30
PA8550201A1 (es) 2003-02-14
US6900336B2 (en) 2005-05-31
RU2004104625A (ru) 2005-05-27
DE60208568D1 (de) 2006-03-30
CA2451392A1 (en) 2003-01-30
AU2002328855B2 (en) 2005-11-24
ATE315022T1 (de) 2006-02-15
BR0211201A (pt) 2004-07-13
EP1409455B1 (en) 2006-01-04
UY27384A1 (es) 2003-01-31
DE60208568T2 (de) 2006-10-05
EP1409455A1 (en) 2004-04-21
RU2288913C2 (ru) 2006-12-10
US20030120079A1 (en) 2003-06-26
KR20040015364A (ko) 2004-02-18
PL368046A1 (en) 2005-03-21
JP2004521954A (ja) 2004-07-22
ES2254726T3 (es) 2006-06-16
MXPA04000456A (es) 2004-03-18

Similar Documents

Publication Publication Date Title
PE20030257A1 (es) Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
YU68102A (sh) Derivati karboksilne kiseline kao ip antagonisti
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
HK1074842A1 (en) Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
PL1660484T3 (pl) Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
SE0301371D0 (sv) New Compounds
ECSP034870A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
MX2008000781A (es) Derivados de triazol substituidos y su uso como antagonistas del receptor neuroquinina 3.

Legal Events

Date Code Title Description
FD Application declared void or lapsed